- In late May 2026, Ituran Location and Control reported first-quarter 2026 results showing higher revenue of US$102.67 million and net income of US$16.77 million year over year, alongside a US$0.50 per-share dividend approval, an expanded US$49.00 million buyback authorization, and a broad shelf registration filing.
- The combination of stronger quarterly earnings with concurrent capital return measures and financing flexibility offers fresh insight into how Ituran is balancing growth investment with shareholder distributions.
- We’ll now examine how the stronger first-quarter earnings, alongside the enhanced buyback authorization, may affect Ituran’s existing investment narrative.
Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
Ituran Location and Control Investment Narrative Recap
To own Ituran Location and Control, you need to believe in its ability to keep growing its connected car and telematics footprint while managing currency swings, product mix pressure, and margin risk. The stronger first quarter, combined with active capital returns, supports the near term focus on execution in OEM and insurance telematics, while the biggest watchpoint remains how mix and lower margin contracts might influence profitability. The latest announcements do not materially change that short term balance of catalyst and risk.
The expanded US$49.00 million buyback authorization sits at the center of this update, because it directly links recent earnings strength to how the company is using surplus cash. Alongside the US$0.50 per share dividend and the new shelf registration, it frames how Ituran is positioning itself to keep funding subscriber and OEM growth while still returning capital, which matters if subscriber additions or lower ARPU segments start to pressure margins.
Yet even with solid recent results, investors should still be watching currency volatility and its impact on reported earnings...
Read the full narrative on Ituran Location and Control (it's free!)
Ituran Location and Control's narrative projects $468.7 million revenue and $77.1 million earnings by 2029. This requires 9.3% yearly revenue growth and about a $19 million earnings increase from $58.0 million today.
Uncover how Ituran Location and Control's forecasts yield a $63.50 fair value, a 3% downside to its current price.
Exploring Other Perspectives
Simply Wall St Community members currently place fair value for Ituran between US$46.44 and US$63.50 across 2 independent views, underscoring how far opinions can stretch. Against that backdrop, the ongoing risk from currency volatility and regional product mix keeps the range of possible outcomes wide, so it is worth comparing several viewpoints before forming a view on the company’s prospects.
Explore 2 other fair value estimates on Ituran Location and Control - why the stock might be worth 29% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Ituran Location and Control research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Ituran Location and Control research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ituran Location and Control's overall financial health at a glance.
Interested In Other Possibilities?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com